Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer

Cathryn B. Crockett, Pamela Samson, Robert Chuter, Michael Dubec, Corinne Faivre-Finn, Olga L. Green, Sara L. Hackett, Fiona McDonald, Clifford Robinson, Anna Maria Shiarli, Michael W. Straza, Joost J.C. Verhoeff, Maria Werner-Wasik, Gregory Vlacich, David Cobben

Research output: Contribution to journalArticlepeer-review


Curative-intent radiotherapy plays an integral role in the treatment of lung cancer and therefore improving its therapeutic index is vital. MR guided radiotherapy (MRgRT) systems are the latest technological advance which may help with achieving this aim. The majority of MRgRT treatments delivered to date have been stereotactic body radiation therapy (SBRT) based and include the treatment of (ultra-) central tumors. However, there is a move to also implement MRgRT as curative-intent treatment for patients with inoperable locally advanced NSCLC. This paper presents the initial clinical experience of using the two commercially available systems to date: the ViewRay MRIdian and Elekta Unity. The challenges and potential solutions associated with MRgRT in lung cancer will also be highlighted.

Original languageEnglish
Article number617681
JournalFrontiers in Oncology
Publication statusPublished - 10 Mar 2021


  • adaptive
  • external beam radiotherapy
  • image-guided radiotherapy (IGRT)
  • magnetic resonance imaging (MRI)
  • MR-guided radiotherapy (MRgRT)
  • non-small cell lung cancer (NSCLC)
  • stereotactic body radiation therapy (SBRT)

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this